Health Professionals

Metastatic Melanoma Study Finds Immunotherapy Resistance Mutations in Immune-Linked Genes

NEW YORK – A research team led by investigators at the Dana-Farber Cancer Institute and the Broad Institute has uncovered somatic mutations linked to immunotherapy resistance in metastatic melanoma patients who experienced disease recurrence and acquired drug resistance after an initial response to immune checkpoint immunotherapy (ICI).

Read More

Dr Faries on Emerging CAR T-Cell and TCR Cell Therapies in Melanoma

Mark Faries, MD, surgical oncologist, Cedars?Sinai, The Angeles Clinic and Research Institute; associate director, Surgical Oncology Experimental Therapeutics, Cedars Sinai Department of Surgery; and head, surgical oncology, Cedars-Sinai Medical Center, discusses how CAR T-cell therapies and transgenic T-cell receptor (TCR) cell therapies compare with current tumor-infiltrating lymphocyte (TIL) approaches in melanoma.

Read More
MRV News
Melanoma News
Archive
Menu